Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seragon Pharmaceuticals Inc.

Blocking and depleting receptors in estrogen-dependent tumors

This article was originally published in Start Up

Executive Summary

Seragon Pharmaceuticals Inc. spun out of Aragon Pharmaceuticals just days before J&J acquired it in 2013. Like Aragon, Seragon's mission is to develop orally active selective estrogen receptor degraders (SERDs) as treatments for cancers fueled by estrogen.


Related Content

Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Strategic Spin-Outs: Biotechs Structure Their Progeny For Success


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts